Sepracor Licenses Late-Stage Anti-Epileptic From Portuguese Pharma Bial
Late 2008/early 2009 NDA filing targeted for the new chemical entity as an adjunct therapy to improve control of epileptic seizures.
Late 2008/early 2009 NDA filing targeted for the new chemical entity as an adjunct therapy to improve control of epileptic seizures.